

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bendele et al.

Serial No.: Not Yet Received

Group Art Unit No.: 1646

Filed: July 17, 2001

Examiner: E. O'Hara

For: COMBINATION THERAPY USING A TNF BINDING
PROTEIN FOR TREATING TNF-MEDIATED
DISEASES

Docket No.: A-430F

Jc821 U.S. PRO
09/907263
07/17/01#5
Agj
#1/1/02INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form. The relevance of each listed reference is discussed in the following paragraphs.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/326,394, filed June 4, 1999, with the exception of Ref. No. B033 submitted herewith. The present application is a divisional of this prior application which is relied upon for an earlier filing date under 35 USC 120.]

Applicant's) position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360689926US

Date of Deposit: July 17, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed NameLynne Buchsbaum
Signature

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Timothy J. Gaul

Attorney for Applicants

Registration No.: 33,111

Phone: (805) 447-2688

Date: July 17, 2001

Please send all future correspondence to:

US Patent Operations/ TJG

Dept. 4300, M/S 27-4-A

AMGEN INC.

One Amgen Center Drive

Thousand Oaks, California 91320-1799